TransThera 药捷安康

TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

DISSOLUTION OF THE SUPERVISORY COMMITTEE AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION, THE RULES OF PROCEDURE OF SHAREHOLDERS' GENERAL MEETINGS AND THE RULES OF PROCEDURE OF THE BOARD OF DIRECTORS

The board of directors (the "**Board**") of TransThera Sciences (Nanjing), Inc. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that, in order to adapt to the newly revised Company Law of the People's Republic of China, further optimize the corporate governance structure and in accordance with the *Company Law of the People's Republic of China*, the *Guidelines on the Articles of Association of Listed Companies* (《上市公司章程指引》) and other relevant laws and regulations, rules and other regulatory documents, the Company proposes to dissolve the supervisory committee of the Company (the "**Supervisory Committee**") and abolish the Rules of Procedure of the Supervisory Committee of TransThera Sciences (Nanjing), Inc. The powers and functions of the Supervisory Committee shall be exercised by the audit committee of the Board, and the provisions involving the Supervisory Committee and supervisors in various rules and regulations of the Company shall no longer apply.

Meanwhile, the Company proposes to amend the Articles of Association of TransThera Sciences (Nanjing), Inc. (the "**Articles of Association**") (the "**Amendments**"). In view of the proposed Amendments to the Articles of Association, the Board also proposes to amend the Rules of Procedures of Shareholders' General Meetings of TransThera Sciences (Nanjing), Inc. (the "**Rules of Procedure of Shareholders' General Meetings**") and the Rules of Procedures of the Board of Directors of TransThera Sciences (Nanjing), Inc. (the "**Rules of Procedure of the Board of Directors**") to align them with the Amendments.

The proposed Amendments to the Articles of Association and the adoption of the amended Articles of Association are subject to the consideration and approval by the shareholders of the Company (the "**Shareholders**") by way of a special resolution at the forthcoming annual general meeting of the Company (the "**AGM**"). The proposed amendments to the Rules of Procedure of Shareholders' General Meetings and the Rules of Procedure of the Board of Directors are subject to the consideration and approval by the Shareholders by way of ordinary resolutions at the AGM.

Upon the amended Articles of Association taking effect, the current members of the Supervisory Committee shall cease to hold office as supervisors and related positions in the Supervisory Committee. The members of the Supervisory Committee have confirmed that they have no disagreement with the Board and there are no other matters relating to the dissolution of the Supervisory Committee that need to be brought to the attention of the Shareholders and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Company will propose at the AGM for the Shareholders to consider and, if thought fit, approve the authorization of the Board and its authorized persons to handle the registration and filing procedures with the relevant market supervision and administration authority regarding the Amendments to the Articles of Association, the changes of which shall be subject to the final version approved by the relevant market supervision and administration authority. A circular containing, among other things, details of the Amendments to the Articles of Association, the Rules of Procedure of Shareholders' General Meetings and the Rules of Procedure of the Board of Directors, together with the notice of the AGM, will be published on the website of the Company (**https://www.transthera.com/**) and the website of the Stock Exchange (**http://www.hkexnews.hk**) in due course.

By order of the Board
TransThera Sciences (Nanjing), Inc.
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, March 31, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.